retatrutide trial dosing just posted the biggest weight-loss numbers ever recorded for a drug — 28.3% (≈70 lb) average in Phase 3, with 45% of people hitting 30%+ loss, territory once reserved for bariatric retatrutide clinical trial weight loss

GLP-1 therapies are being produced at extremely high volumes, often requiring multiple dedicated production lines and multi-year commitments

2025 Feb;39(2):e153-e154

Facing increasing revenue pressures, the state expects to save $17 million per year from the move

There have been rare reports of kidney and liver damage with high-dose chromium use

American Board of Pediatrics (ABP) Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1.50 MOC points in the American Board of Pediatrics (ABP) Maintenance of Certification (MOC) program

Muscle Preservation Focus GLP-1 medications can cause muscle loss if not managed properly